Last reviewed · How we verify
Prurisol
Prurisol is a Small molecule drug developed by Cellceutix Corporation. It is currently in Phase 2 development. Also known as: Purisol, 50mg tablet, abacavir acetate.
Prurisol is a small molecule used in the treatment of psoriasis, specifically plaque psoriasis and chronic stable plaque psoriasis. It is a bioequivalent form of abacavir sulfate, as demonstrated in a pharmacokinetic study.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Prurisol |
|---|---|
| Also known as | Purisol, 50mg tablet, abacavir acetate |
| Sponsor | Cellceutix Corporation |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers (PHASE1)
- Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis (PHASE2)
- Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prurisol CI brief — competitive landscape report
- Prurisol updates RSS · CI watch RSS
- Cellceutix Corporation portfolio CI
Frequently asked questions about Prurisol
What is Prurisol?
Who makes Prurisol?
Is Prurisol also known as anything else?
What development phase is Prurisol in?
Related
- Manufacturer: Cellceutix Corporation — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Purisol, 50mg tablet, abacavir acetate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing